Literature DB >> 35275694

Exercise Tolerance in Patients With Idiopathic Pulmonary Fibrosis, Effect of Supplemental Oxy-Gen.

J Chlumský1, L Stehlík, M Šterclová, J Smetanová, O Zindr.   

Abstract

Exercise tolerance in patients with idiopathic pulmonary fibrosis IPF is mainly limited by mechanical constrain of ventilation and high physiologic dead space. Oxygen enriched gas inhalation seems to increase ventilatory efficiency by reduction of dead space to tidal volume ratio (VD/VT) which probably mirrors improved pulmonary capillary flow and leads to longer physical tolerance at lower level of minute ventilation. The effect is noticeable at FIO2 that can be delivered in rehabilitation purposes or daily living activities.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35275694      PMCID： PMC9150554          DOI： 10.33549/physiolres.934764

Source DB:  PubMed          Journal:  Physiol Res        ISSN： 0862-8408            Impact factor:   2.139


  15 in total

1.  Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis.

Authors:  K Miki; R Maekura; T Hiraga; Y Okuda; T Okamoto; A Hirotani; T Ogura
Journal:  Respir Med       Date:  2003-05       Impact factor: 3.415

Review 2.  Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia.

Authors:  Lauren K Troy; Iven H Young; Edmund M T Lau; Tamera J Corte
Journal:  Respirology       Date:  2015-09-29       Impact factor: 6.424

Review 3.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.

Authors:  Steven D Nathan; Paul W Noble; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

4.  Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence.

Authors:  Michele R Schaeffer; Yannick Molgat-Seon; Christopher J Ryerson; Jordan A Guenette
Journal:  Eur Respir Rev       Date:  2017-08-09

5.  Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation.

Authors:  Shinichi Arizono; Taiki Furukawa; Hiroyuki Taniguchi; Koji Sakamoto; Tomoki Kimura; Kensuke Kataoka; Tomoya Ogawa; Fumiko Watanabe; Yasuhiro Kondoh
Journal:  Respirology       Date:  2020-05-05       Impact factor: 6.424

Review 6.  Physiology of the lung in idiopathic pulmonary fibrosis.

Authors:  Laurent Plantier; Aurélie Cazes; Anh-Tuan Dinh-Xuan; Catherine Bancal; Sylvain Marchand-Adam; Bruno Crestani
Journal:  Eur Respir Rev       Date:  2018-01-24

Review 7.  ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases.

Authors:  Thomas Radtke; Sarah Crook; Georgios Kaltsakas; Zafeiris Louvaris; Danilo Berton; Don S Urquhart; Asterios Kampouras; Roberto A Rabinovich; Samuel Verges; Dimitris Kontopidis; Jeanette Boyd; Thomy Tonia; Daniel Langer; Jana De Brandt; Yvonne M J Goërtz; Chris Burtin; Martijn A Spruit; Dionne C W Braeken; Sauwaluk Dacha; Frits M E Franssen; Pierantonio Laveneziana; Ernst Eber; Thierry Troosters; J Alberto Neder; Milo A Puhan; Richard Casaburi; Ioannis Vogiatzis; Helge Hebestreit
Journal:  Eur Respir Rev       Date:  2019-12-18

8.  Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up.

Authors:  C Agustí; A Xaubet; A G Agustí; J Roca; J Ramirez; R Rodriguez-Roisin
Journal:  Eur Respir J       Date:  1994-04       Impact factor: 16.671

9.  Pathophysiology of activity limitation in patients with interstitial lung disease.

Authors:  J E Hansen; K Wasserman
Journal:  Chest       Date:  1996-06       Impact factor: 9.410

10.  Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease.

Authors:  Michele R Schaeffer; Christopher J Ryerson; Andrew H Ramsook; Yannick Molgat-Seon; Sabrina S Wilkie; Satvir S Dhillon; Reid A Mitchell; A William Sheel; Nasreen Khalil; Pat G Camp; Jordan A Guenette
Journal:  Eur Respir J       Date:  2018-01-18       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.